Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock
Despite rising interest rates and the uncertainty of midterm elections, Asad Haider of Goldman Sachs sees promise in Big Pharma and biotech.
Despite rising interest rates and the uncertainty of midterm elections, Asad Haider of Goldman Sachs sees promise in Big Pharma and biotech.